- Deal accelerates the addition of clazakizumab, an anti-IL6 MAB currently in phase III development for treatment of chronic active antibody-mediated rejection, into CSL Behring's portfolio KING OF ...

KING OF PRUSSIA, Pa., Nov. 2, 2020 /PRNewswire/ -- Global biotherapeutics leader CSL Behring announced today that its investigational, plasma-derived hemopexin therapy (CSL889) received orphan drug ...

KING OF PRUSSIA, Pa., March 4, 2016 /PRNewswire/ -- CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has approved IDELVION® [Coagulation Factor IX (Recombinant), Albumin ...

CSL is well ahead of Grifols in evolving its business to recombinant products and Grifols is not pursuing gene therapy at present. CSL is also the only player with a direct presence in China which is ...

CSL Limited, a biotechnology company that produce many of its biological products from plasma, is diversifying its portfolio and its drug pipeline through its largest ever acquisition: the purchase of ...

The Pennsylvania biotech company CSL Behring says it is on track to file for approval of its hemophilia B gene therapy by the end of June after releasing pivotal data showing statistical superiority ...

"CSL Behring has a broad portfolio of coagulation products, a long history of advancing coagulation therapy, and a thorough understanding of the challenges facing the bleeding disorders community," ...

Moscow opening reinforces CSL Behring's promise to deliver its world-class therapies to patients with rare and serious diseases around the world. KING OF PRUSSIA, Pa. — 08 December 2015 - Global ...

- 4- and 5-gram ZEMAIRA ® vials may reduce the number of vials necessary for reconstitution, thereby providing convenience and lowering package waste KING OF PRUSSIA, Pa., Jan. 2, 2024 /PRNewswire/ -- ...

TAIPEI, Oct. 24, 2021 /PRNewswire/ -- HCmed Innovations (HCmed), a Taiwanese company that focuses on the development of vibrating mesh nebulizers, today announced the successful completion of the ...

MELBOURNE, Australia & ST. GALLEN, Switzerland--(BUSINESS WIRE)--Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR CSL Behring AG, Berne, Switzerland, a wholly-owned subsidiary of global ...

- Builds on CSL Behring's promise and commitment to the transplant community - Deal accelerates the addition of clazakizumab, an anti-IL6 MAB currently in phase III development for treatment of ...